A Study of ARRY-502 in Patients With Persistent Asthma

Completed · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the US will be enrolled in this study.

Key facts

Study ID
NCT01561690
Run by
Pfizer
People needed
184
Starts
2012-04-02
Expected to finish
2013-06-10
Last updated by the study team
2023-10-30

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.